SLC1A3 contributes to L‐asparaginase resistance in solid tumorsJianhui Sun, Reuven Agami, Remco Nagel et al.|The EMBO Journal|2019Cited by 74
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancerSander Mertens, Hugo J.G. Snippert, Maarten A. Huismans et al.|Cell Reports|2023Cited by 72
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J. Frank, Sara Mainardi, Antonio Mulero‐Sánchez et al.|Cell Reports Medicine|2022Cited by 39
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapseMengnuo Chen, René Bernards, Sara Mainardi et al.|Cell Reports Medicine|2024Cited by 34
Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translationJulien Champagne, Reuven Agami, Morten M. Nielsen et al.|Immunity|2025Cited by 13